Tranexamic acid is under clinical development by Hyloris Pharmaceuticals and currently in Phase III for Bleeding And Clotting Disorders. According to GlobalData, Phase III drugs for Bleeding And Clotting Disorders have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tranexamic acid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tranexamic acid overview
Tranexamic acid (HY-004) is under development for the treatment of oral (dental) bleeding. It is formulated as a rinse and is administered through oral route.
It was also under development for hemophilia.
Hyloris Pharmaceuticals overview
Hyloris Pharmaceuticals (Hyloris) is a biopharmaceutical company that focuses on developing value-added medicines for underserved patient populations. The company’s product pipeline includes various drug candidates such as Sotalol IV and Dofetilide IV to treat atrial fibrillation; Aspirin IV for treatment of acute coronary syndrome; and Milrinone to treat advanced heart failure (LVAD). Its pipeline also includes Metolazone IV against congestive heart failure; HY-074 to treat acute coronary syndrome; and HY-075 for treatment of coronary heart disease. Hyloris works in collaboration with AltaThera Pharmaceuticals. Hyloris is headquartered in Liege, Belgium.
For a complete picture of Tranexamic acid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
